[{"id":"68568d37-21f2-4b3b-a994-81af7518adda","acronym":"AdvanTIG-202","url":"https://clinicaltrials.gov/study/NCT04693234","created_at":"2021-01-19T20:49:03.675Z","updated_at":"2024-07-02T16:35:31.388Z","phase":"Phase 2","brief_title":"AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer","source_id_and_acronym":"NCT04693234 - AdvanTIG-202","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • ociperlimab (BGB-A1217) • mipsagargin (G-202)"],"overall_status":"Completed","enrollment":" Enrollment 178","initiation":"Initiation: 02/15/2021","start_date":" 02/15/2021","primary_txt":" Primary completion: 06/16/2022","primary_completion_date":" 06/16/2022","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2023-10-27"},{"id":"7e38eb9d-5aae-4a5a-9e6d-998c32e68abe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02607553","created_at":"2021-01-19T11:19:14.855Z","updated_at":"2024-07-02T16:37:25.084Z","phase":"Phase 2","brief_title":"Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA","source_id_and_acronym":"NCT02607553","lead_sponsor":"GenSpera, Inc.","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e mipsagargin (G-202)"],"overall_status":"Completed","enrollment":" Enrollment 2","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 02/01/2017","study_completion_date":" 02/01/2017","last_update_posted":"2017-02-24"}]